Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma. Issue 22 (25th October 2021)

• Record Type: Journal Article
• Authors: Kang, Junnan; Zhang, Yizhuo; Ding, Sa; Yasheng, Kalbinur; Li, Yueyang; Yu, Yong; Wang, Yafei; Tian, Chen
• Is Part Of: Journal of cellular and molecular medicine. Volume 25:Issue 22(2021)
• Page Start: 10770
• Page End: 10773
• Publication Date: 2021-10-25
• Subjects: chidamide -- conditioning regimen -- high dose rituximab -- triple‐hit lymphoma; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.16999
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Triple‐hit lymphoma (THL), which is classified into high‐grade B‐cell lymphoma with rearrangements of MYC, BCL2 and BCL6, presents aggressive biological behaviour. High‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto‐HSCT) is considered to be one of the recommended treatment options. Here, we reported 3 THL patients received carmustine, etoposide, cytarabine and cyclophosphamide (BEAC) combined with chidamide and high‐dose rituximab conditioning regimen and found that this conditioning showed good efficacy and tolerance without increase of adverse events.